

AI  
been pre-digested with BamHI and Not I restriction enzymes. The recombinant plasmids for cases (A), (B) and (C) were examined by sequencing in per-se known manner (Pharmacia (TM) kit).

**Generation of recombinant baculoviruses:**

Insect cells of *Spodoptera frugiperda* (sf21) were grown in 30 mm dishes until 80% confluent, at 27°C with TNMFH medium (Sigma) supplemented with 1 0% foetal--

**In the Abstract:**

Please add the following abstract as page 15 of the specification:

**--ABSTRACT**

AD  
Modified virus-like particles (VLPs) can comprise fusion proteins having sequence from a major coat protein of papovavirus, e.g. L1 protein and HPV 16 or 18, in which the N-terminal of the sequence derived from the major coat protein is fused to a further peptide sequence. The VLPs can contain a full sequence of an L1 protein, or an L1 sequence with an N-terminal deletion, or an L1 sequence with an amino acid substitution mutation, and optionally a C-terminal L1 sequence deletion. The peptide sequence fused to the N-terminal can be immunogenic, e.g. from a protein of a pathogen such as a virus. The further peptide sequence can provide a binding domain for affinity purification of the VLP. Modified VLPs can retain the native conformation of the VLP structure while also presenting to the immune system of a subject immunized with the modified VLPs an epitope present on an N-terminal extension of the major coat protein sequence. Corresponding polynucleotides, expression vectors, plasmids, vectors and cells containing such polynucleotides are disclosed.--

**REMARKS**

This Response and Second Preliminary Amendment is submitted to recite sequence numbers for the sequences set forth in the application and to correct a typographical error, and to add the Abstract. No new matter is added. Entry of this amendment is respectfully requested.